Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Novel Agents for Relapsing Forms of Multiple Sclerosis.
The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.
A new computerised cognitive test for the detection of information processing speed impairment in multiple sclerosis.
Vitamin d and multiple sclerosis.
Optical Coherence Tomography versus Visual Evoked Potentials in detecting subclinical visual impairment in multiple sclerosis.
Drug therapy for multiple sclerosis.
LSN MS guidelines for the management of multiple sclerosis.
Cannabinoids decrease the th17 inflammatory autoimmune phenotype.
Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients.
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Longitudinal association between depressive symptoms and walking impairment in people with relapsing-remitting multiple sclerosis.
Neurofilament-tubulin binding site peptide NFL-TBS.40-63 increases the differentiation of oligodendrocytes in vitro and partially prevents them from lysophosphatidyl choline toxiciy.
Impaired Object Handling during Bimanual Task Performance in Multiple Sclerosis.
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
The organization of the sphingosine 1-phosphate signaling system.
Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys.
Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review.
Predictors of driving in individuals with relapsing-remitting multiple sclerosis.
Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery.
Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis.
Endovascular Treatment of Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: A retrospective study.
Cognition and eye movements: assessment of cerebral dysfunction.
The visual pathway as a model to understand brain damage in multiple sclerosis.
Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis; From the Safety Assessment of Biologic ThERapy (SABER) Study.
Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity.
Pages
« first
‹ previous
…
255
256
257
258
259
260
261
262
263
…
next ›
last »